 MINNEAPOLIS--BUSINESS WIRE--DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the initiation of the first site for its pivotal ReMEDy2 Trial, a Phase 23 clinical study of DM199 for the treatment of acute ischemic stroke AIS. The ReMEDy2 Trial is a randomized, double-blind, placebo-controlled Phase 23 adaptive trial designed to enroll 350 patients at 7 